Global biopharma mergers and acquisitions surpassed USD 106 billion across 201 transactions in the first half of 2026, placing the sector firmly on course for its highest dealmaking volume since the pre-pandemic peak, according to data published in June 2026. The acceleration reflects a convergence of factors: patent expiries threatening an estimated USD 200 billion in branded pharmaceutical revenues through 2030, a more permissive regulatory posture toward M&A, and renewed confidence in public markets that has improved both buyer balance sheets and target valuations.

The first half of June alone produced a cluster of headline transactions. On June 9, GSK announced it had entered a definitive agreement to acquire Nuvalent, a Boston-based clinical-stage company focused on precision oncology. Nuvalent’s lead assets include ROS1 and ALK inhibitors designed to overcome resistance mutations that limit first-generation agents in non-small cell lung cancer. GSK’s entry into precision oncology via this acquisition signals a portfolio shift for the British pharma giant, which has historically been stronger in vaccines, immunology, and infectious disease.

On June 8, Johnson and Johnson agreed to acquire Firefly Bio for USD 1 billion in cash. Firefly has built a degrader antibody conjugate platform, a technology that combines antibody-directed delivery with targeted protein degradation to attack tumour-driving proteins that are resistant to conventional inhibitor-based approaches. For J&J Innovative Medicine, the acquisition adds a next-generation oncology modality to a pipeline already deepened by earlier transactions.

Also on June 8, Incyte Corporation announced a USD 1.25 billion definitive agreement to acquire Vega Therapeutics, which is developing therapies for inflammatory and autoimmune diseases. Biogen, meanwhile, separately announced it is acquiring RayThera for up to USD 1 billion to expand its immunology pipeline beyond its historic neuroscience focus.

Eli Lilly, flush with capital from its GLP-1 franchise, announced the concurrent acquisitions of Curevo, LimmaTech, and Vaccine Company for a combined total of approximately USD 3.8 billion, diversification moves that add infectious disease assets to a metabolic-disease-heavy portfolio.

The pace and scale of these transactions raise important questions for earlier-stage companies about exit strategies and for acquirers about integration capacity. For the emerging Australian biotech sector, where companies conducting clinical trials through specialised CRO networks are building INDs and Phase I/II programs, the appetite from large pharma for validated mechanisms represents a genuine exit pathway, provided asset differentiation is established early and clinical data packages are assembled to international standards.